lapatinib has been researched along with Central Nervous System Neoplasms in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aglietta, M; Ciardiello, F; Lonardi, S; Marsoni, S; Martino, C; Sartore-Bianchi, A; Siena, S | 1 |
| Dodwell, D; Heudtlass, P; Johnston, S; Marshall, H; Murden, G; Oughton, JB; Passant, H; Pottinger, A; Price, C; Rizwanullah, M; Seligmann, JF; Velikova, G; Wright-Hughes, A | 1 |
| de Stanchina, E; Fleisher, M; Kemeny, MM; Li, BT; Morikawa, A; Norton, L; Patil, S; Pentsova, E; Seidman, AD; Tang, K; Van Poznak, C | 1 |
| Blaney, SM; Boyett, JM; Fouladi, M; Gajjar, A; Geyer, JR; Gilbertson, RJ; Goldman, S; Kun, LE; Onar-Thomas, A; Packer, RJ; Schaiquevich, P; Stewart, CF | 1 |
| Blackwell, K; Diéras, V; Guardino, E; Huober, J; Krop, IE; Lin, NU; Lu, M; Miles, D; Samant, M; Welslau, M | 1 |
| Bregni, G; de Braud, F; Di Cosimo, S; Galli, G; Gevorgyan, A; Porcu, L; Serpico, D; Tessari, A; Torri, V | 1 |
| Blaney, SM; Boyett, JM; Fouladi, M; Gajjar, A; Gilbertson, RJ; Kun, LE; Onar-Thomas, A; Packer, RJ; Schaiquevich, P; Stewart, CF | 1 |
| Chi, SN; Forsyth, P; Jayanthan, A; Lun, X; Narendran, A; Obaid, H; Ruan, Y; Singh, A; Smith, A; Strother, D | 1 |
6 trial(s) available for lapatinib and Central Nervous System Neoplasms
| Article | Year |
|---|---|
Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Central Nervous System Neoplasms; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Male; Middle Aged; Protein Kinase Inhibitors; Receptor, ErbB-2; Recurrence; Trastuzumab; Treatment Outcome | 2020 |
Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastu
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Central Nervous System Neoplasms; Female; Humans; Lapatinib; Middle Aged; Prognosis; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Trastuzumab | 2020 |
Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Central Nervous System Neoplasms; Drug Administration Schedule; Humans; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Receptor, ErbB-2; Treatment Outcome | 2019 |
A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
Topics: Adolescent; Antineoplastic Agents; Blotting, Western; Central Nervous System Neoplasms; Child; Child, Preschool; Ependymoma; ErbB Receptors; Female; Glioma; Humans; Infant; Lapatinib; Male; Medulloblastoma; Neoplasm Grading; Quinazolines; Treatment Outcome; Young Adult | 2013 |
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Central Nervous System Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Lapatinib; Maytansine; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Young Adult | 2015 |
Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Central Nervous System Neoplasms; Child; Child, Preschool; Diarrhea; ErbB Receptors; Exanthema; Fatigue; Female; Humans; Infant; Lapatinib; Male; Maximum Tolerated Dose; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Steroids; Treatment Outcome; United States; Young Adult | 2010 |
2 other study(ies) available for lapatinib and Central Nervous System Neoplasms
| Article | Year |
|---|---|
Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Central Nervous System Neoplasms; Disease Progression; Female; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Time Factors; Trastuzumab; Treatment Outcome | 2015 |
Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Survival; Cells, Cultured; Central Nervous System Neoplasms; Child; ErbB Receptors; Female; Humans; Infant; Lapatinib; Male; Mice; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Rhabdoid Tumor; Signal Transduction | 2013 |